Eli Lilly Stock Falls as It Closes in on a $2 Billion Deal. Here’s Why.
Barrons
—
Eli Lilly’s deal for Kelonia, which develops blood cancer therapies, could come as early as Monday.
- Eli Lilly to buy Boston biotech Kelonia for $3.25 billion Boston Globe —
- Eli Lilly agrees to buy cancer biotech Kelonia for up to $7 billion Boston Globe —
- Eli Lilly Announces $7 Billion Deal. What It Means for the Stock. Barrons —
- Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion CNBC —